金域医学(603882) - 2025 Q2 - 季度业绩预告

2025 Semi-Annual Pre-loss Announcement Current Period Performance Forecast The company anticipates a loss for the first half of 2025, with net profit attributable to shareholders of the listed company projected between -65 million RMB and -95 million RMB, and net profit after deducting non-recurring gains and losses estimated between -78 million RMB and -110 million RMB 2025 Semi-Annual Performance Forecast | Financial Indicator | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | -65 Million RMB to -95 Million RMB | | Net Profit After Deducting Non-recurring Gains and Losses | -78 Million RMB to -110 Million RMB | - The forecasted performance has not been audited by an accounting firm[3] Prior Period Performance Overview The company achieved profitability in the same period of 2024, with net profit attributable to shareholders of 89.65 million RMB, net profit after deducting non-recurring gains and losses of 74.25 million RMB, and basic earnings per share of 0.19 RMB 2024 Semi-Annual Prior Period Performance | Financial Indicator | 2024 Prior Period Amount (RMB) | | :--- | :--- | | Total Profit | 96.88 Million RMB | | Net Profit Attributable to Shareholders of Listed Company | 89.65 Million RMB | | Net Profit After Deducting Non-recurring Gains and Losses | 74.25 Million RMB | | Basic Earnings Per Share | 0.19 RMB | Main Reasons for Current Period Pre-loss The pre-loss is primarily due to lower-than-expected business revenue influenced by the macroeconomic environment and proactive customer structure optimization, coupled with high fixed costs reducing operating leverage, and an estimated significant credit impairment loss of approximately 260 million to 290 million RMB due to extended accounts receivable collection periods - Business revenue fell short of expectations due to economic cycles, industry policies, and proactive customer structure optimization, while high fixed costs led to decreased operating leverage efficiency[6] - An estimated credit impairment loss of approximately 260 million to 290 million RMB is expected for the first half of 2025 due to extended collection periods for some accounts receivable[6] - The company will continue to focus on its core medical testing business, strengthen internal operations, and leverage digital and intelligent innovation to build long-term core competitiveness[6] Risk Warning and Other Notes The company confirms no significant uncertainties affect the accuracy of this performance forecast, but emphasizes that the forecasted data is preliminary and subject to the final 2025 semi-annual report - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[7] - This forecast represents preliminary accounting data, with final accurate financial figures subject to the company's officially disclosed 2025 semi-annual report[8]